Zacks Research Has Bullish Estimate for BMY Q2 Earnings

Bristol Myers Squibb Company (NYSE:BMY) – Investment analysts at Zacks Research upped their Q2 2026 earnings per share (EPS) estimates for shares of Bristol Myers Squibb in a report issued on Tuesday, December 16th. Zacks Research analyst Team now expects that the biopharmaceutical company will earn $1.67 per share for the quarter, up from their previous forecast of $1.66. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.74 per share. Zacks Research also issued estimates for Bristol Myers Squibb’s FY2026 earnings at $6.02 EPS and Q1 2027 earnings at $1.36 EPS.

BMY has been the topic of a number of other research reports. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Morgan Stanley reiterated an “underweight” rating and issued a $37.00 price target (up from $36.00) on shares of Bristol Myers Squibb in a research report on Friday, December 12th. Truist Financial set a $65.00 price objective on shares of Bristol Myers Squibb in a research report on Wednesday, December 3rd. HSBC reaffirmed a “hold” rating and issued a $53.00 target price on shares of Bristol Myers Squibb in a report on Wednesday, December 10th. Finally, The Goldman Sachs Group reissued a “neutral” rating and set a $57.00 price target (up previously from $51.00) on shares of Bristol Myers Squibb in a report on Tuesday, December 2nd. Five investment analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $54.62.

Bristol Myers Squibb Trading Up 1.5%

Bristol Myers Squibb stock opened at $54.15 on Thursday. Bristol Myers Squibb has a 52-week low of $42.52 and a 52-week high of $63.33. The company has a market cap of $110.24 billion, a P/E ratio of 18.29, a P/E/G ratio of 8.16 and a beta of 0.29. The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39. The business has a 50-day simple moving average of $47.73 and a two-hundred day simple moving average of $47.15.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, topping the consensus estimate of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The company had revenue of $12.22 billion during the quarter, compared to analyst estimates of $11.75 billion. During the same quarter in the previous year, the company posted $1.80 earnings per share. Bristol Myers Squibb’s revenue was up 2.8% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS.

Institutional Investors Weigh In On Bristol Myers Squibb

A number of institutional investors and hedge funds have recently bought and sold shares of BMY. Trifecta Capital Advisors LLC purchased a new stake in shares of Bristol Myers Squibb during the second quarter worth about $25,000. Darwin Wealth Management LLC purchased a new stake in Bristol Myers Squibb during the 2nd quarter valued at approximately $25,000. CBIZ Investment Advisory Services LLC raised its position in shares of Bristol Myers Squibb by 66.0% during the first quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 231 shares during the last quarter. GKV Capital Management Co. Inc. purchased a new position in shares of Bristol Myers Squibb in the first quarter worth $36,000. Finally, Harbor Capital Advisors Inc. boosted its position in shares of Bristol Myers Squibb by 107.2% during the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 313 shares during the last quarter. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, February 2nd. Investors of record on Friday, January 2nd will be paid a dividend of $0.63 per share. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date is Friday, January 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.7%. Bristol Myers Squibb’s dividend payout ratio is presently 83.78%.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers publicly announced an agreement with the U.S. government to improve affordability and access to medicines — a company release that frames the deal as preserving market access while responding to pricing pressures. This reduces regulatory uncertainty and the risk of punitive measures that could have hurt sales. Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
• Positive Sentiment: BMY and partner BioNTech reported progress in immunotherapy clinical programs (first-line liver cancer and a kidney‑cancer trial update), which add long-term commercial optionality if late‑stage data confirms benefit. These pipeline moves support upside beyond near‑term pricing headwinds. New Pumitamig Kidney Cancer Trial Adds Long-Term Optionality for Bristol-Myers Squibb and BioNTech
• Positive Sentiment: Analyst and media endorsements are visible: Guggenheim raised/maintained an elevated price target after an FDA priority review and media commentators (including Jim Cramer) are calling BMY a buy/value name — these signals can attract momentum and retail/institutional buyers. Guggenheim sets $62 target on Bristol-Myers Squibb Company (BMY) after FDA priority review
• Neutral Sentiment: Major press outlets report that nine pharma companies (including BMY) struck voluntary price agreements with the White House to link some U.S. prices to lower foreign prices and to avoid potential tariffs — this offers regulatory clarity but also implies longer‑term pricing pressure. Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay
• Neutral Sentiment: Broader coverage (CNBC) confirms multiple large drugmakers are making similar deals with the administration — increases industry momentum toward pricing reforms but spreads the competitive/market impact across peers. Nine of the largest pharma companies ink deals with Trump to lower drug prices
• Neutral Sentiment: BMY set a Q4 2025 earnings release date (Feb. 5, 2026) — a near‑term catalyst investors will watch for sales impact from pricing agreements and pipeline progress. Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026
• Negative Sentiment: Analyst model updates from Zacks Research trimmed several near‑term EPS estimates and cut FY2027 estimates modestly, implying some downward revision risk to earnings expectations if pricing concessions or volume shifts persist. (Zacks research notes summarized across recent releases.)
• Positive Sentiment: Market commentary pieces positioning BMY as a long‑term value stock may attract defensive/value investors given the company’s dividend/cash flow profile and pipeline depth. Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.